GFAP and Parkinson disease: Cross-validation confirmed the stability of the model (AUC = 0.843).<h4>Conclusion</h4>This was the first study to integrate plasma NFL/GFAP, clinical disease duration, and pontine radiomic features to construct a high-precision PD-APS differential model (AUC > 0.87), addressing the limitations of traditional single-mode approaches.